VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

Core Viewpoint - Rosen Law Firm is reminding purchasers of Vistagen Therapeutics, Inc. common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to the company's alleged misleading statements regarding its drug fasedienol [1][3]. Group 1: Class Action Details - Investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable ranking by ISS Securities Class Action Services [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided investors with overly positive information regarding its drug fasedienol, which is in development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - The misleading statements made by the defendants led to investor damages when the true details about the trial were revealed [6].